Dottikon Es (DESN) H1 24/25 earnings summary

Executive summary

• Net sales for H1 2024/25 rose 2.9% year-over-year to CHF 157.0 million, with broad-based growth across products and customers.

• Production output increased 14.6%, but production yield remained constrained by capacity limits, highlighting the need for new API plants now coming online.

• EBITDA fell 9.3% to CHF 47.7 million, mainly due to upfront costs for new plant commissioning and a more material-intensive product mix.

• Net income declined 13.7% to CHF 32.3 million, with a net income margin of 20.5% versus 24.5% a year earlier.

• Cash flow from operating activities dropped to CHF 23.8 million from CHF 50.0 million, mainly due to inventory buildup.

Financial highlights

• Net sales: CHF 157.0 million (+2.9% year-over-year); EBITDA: CHF 47.7 million (-9.3%); EBIT: CHF 37.3 million (-12.3%).

• Net income: CHF 32.3 million (-13.7%); net income margin: 20.5% (prior: 24.5%).

• Material expenses rose 52.6% to CHF 63.6 million due to a more material-intensive product mix and inventory increase.

• Personnel expenses increased 8.8% to CHF 46.4 million, reflecting a 7.8% rise in average staff to 770 FTEs.

• Property, plant, and equipment rose by CHF 62.6 million due to ongoing high investments.

Outlook and guidance

• With new plants starting operations, growth is expected to resume and net sales for FY 2024/25 are projected to exceed the previous year.

• Investments will remain high as new API drying and multipurpose production plants are commissioned.

• The company is preparing for increased demand driven by regulatory, innovation, and repatriation trends in the biopharma market.